Safety and Efficacy of BIA 5-1058 in PAH

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 26, 2019

Primary Completion Date

February 17, 2022

Study Completion Date

February 17, 2022

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Oral zamicastat

Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.

Trial Locations (11)

4020

Ordensklinikum Linz Elisabethinen, Interne 2 - Kardiologie, Angiologie & Interne Intensivmedizin Fadingerstraße 1, Linz

20900

ASST di Monza-Ospedale San Gerardo -Dipartimento di Pneumologia via Pergolesi 33, Monza

28041

"Hospital Universitario 12 de Octubre Avda. de Córdoba, s/n", Madrid

37007

Complejo Asistencial Universitario de Salamanca Pº. San Vicente, 58, Salamanca

39008

Hospital Universitario Marques de Valdecilla Avenida Valdecilla, 25, Santander

01307

Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Pneumologie Fetscherstraße 74, Dresden

00161

AOU di Roma-Policlinico Umberto I-Unità Dipartimentale Malattie del Circolo Polmonare Viale del Policlinico 155, Roma

1769-001

Centro Hospitalar Lisboa Norte, E.P.E. - Hospital Pulido Valente Consulta Externa de Hipertensão Pulmonar Alameda das Linhas de Torres, 117, Lisbon

08036

Hospital Clinic de Barcelona Calle Villarroel, 170, Barcelona

G81 4DY

Golden Jubilee National Hospital Golden Jubilee National Hospital Agamemnon St, Scottish Pulmonary Vascular Unit Golden Jubilee National Hospital, Clydebank

NW3 2QG

Royal Free Hospital Pond Street, London

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT06009185 - Safety and Efficacy of BIA 5-1058 in PAH | Biotech Hunter | Biotech Hunter